Diabetes and Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease

키워드

참고문헌 (90)

1. Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
2. Yang JD, "A global view of hepatocellular carcinoma : trends, risk, prevention and management", Nat Rev Gastroenterol Hepatol, 16, pp.589~604 (2019)
3. Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
4. Finn RS, "Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma", N Engl J Med, 382, pp.1894~1905 (2020)
5. Yang JD, "New advances in the diagnosis and management of hepatocellular carcinoma", BMJ, 371, pp.m3544~ (2020)
6. Kew MC, "Aflatoxins as a cause of hepatocellular carcinoma", J Gastrointestin Liver Dis, 22, pp.305~310 (2013)
7. Huang DQ, "Global epidemiology of NAFLD-related HCC : trends, predictions, risk factors and prevention", Nat Rev Gastroenterol Hepatol, 18, pp.223~238 (2021)
8. Teng PC, "Circulating tumor cells : a step toward precision medicine in hepatocellular carcinoma", J Gastroenterol Hepatol, 37, pp.1179~1190 (2022)
9. Fattovich G, "Hepatocellular carcinoma in cirrhosis : incidence and risk factors", Gastroenterology, 127(5 Suppl 1), pp.S35~S50 (2004)
10. Singal AG, "HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis : a meta-analysis", J Hepatol, 77, pp.128~139 (2022)
11. Noureddin M, "Pathogenesis of NASH : the impact of multiple pathways", Curr Hepatol Rep, 17, pp.350~360 (2018)
12. Le MH, "2019 Global NAFLD prevalence : a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 20, pp.2809~2817 (2022)
13. Shah PA, "NAFLD-related hepatocellular carcinoma: the growing challenge", Hepatology (2022)[DOI]
14. Noureddin M, "Nonalcoholic fatty liver disease, diabetes, obesity, and hepatocellular carcinoma", Clin Liver Dis, 19, pp.361~379 (2015)
15. Pelusi S, "Renin-angiotensin system inhibitors, type 2 diabetes and fibrosis progression : an observational study in patients with nonalcoholic fatty liver disease", PLoS One, 11, pp.e0163069~ (2016)
16. Noureddin M, "Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017-2018 transient elastography data and application of machine learning", Hepatol Commun, 6, pp.1537~1548 (2022)
17. Welzel TM, "Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States", Am J Gastroenterol, 108, pp.1314~1321 (2013)
18. Huang DQ, "Changing global epidemiology of liver cancer from 2010 to 2019 : NASH is the fastest growing cause of liver cancer", Cell Metab, 34, pp.969~977 (2022)
19. Karim MA, "Clinical characteristics and outcomes of nonalcoholic fatty liver diseaseassociated hepatocellular carcinoma in the United States", Clin Gastroenterol Hepatol (2022)[DOI]
20. Dyson J, "Hepatocellular cancer : the impact of obesity, type 2 diabetes and a multidisciplinary team", J Hepatol, 60, pp.110~117 (2014)
21. Estes C, "Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030", J Hepatol, 69, pp.896~904 (2018)
22. Lee YT, "State-level HCC incidence and association with obesity and physical activity in the United States", Hepatology, 74, pp.1384~1394 (2021)
23. Orci LA, "Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease : a systematic review, meta-analysis, and meta-regression", Clin Gastroenterol Hepatol, 20, pp.283~292 (2022)
24. Stine JG, "Systematic review with meta-analysis : risk of hepatocellular carcinoma in nonalcoholic steatohepatitis without cirrhosis compared to other liver diseases", Aliment Pharmacol Ther, 48, pp.696~703 (2018)
25. Tan DJH, "Clinical characteristics, surveillance, treatment allocation, and outcomes of nonalcoholic fatty liver disease-related hepatocellular carcinoma : a systematic review and meta-analysis", Lancet Oncol, 23, pp.521~530 (2022)
26. El-Serag HB, "Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma", Gastroenterology, 126, pp.460~468 (2004)
27. Hassan MM, "Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma", Cancer, 116, pp.1938~1946 (2010)
28. El-Serag HB, "The association between diabetes and hepatocellular carcinoma : a systematic review of epidemiologic evidence", Clin Gastroenterol Hepatol, 4, pp.369~380 (2006)
29. Kanwal F, "Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease", Hepatology, 71, pp.808~819 (2020)
30. Targher G, "The complex link between NAFLD and type 2 diabetes mellitus : mechanisms and treatments", Nat Rev Gastroenterol Hepatol, 18, pp.599~612 (2021)
31. Veldt BJ, "Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus", Hepatology, 47, pp.1856~1862 (2008)
32. Gentile S, "Incidence of altered glucose tolerance in liver cirrhosis", Diabetes Res Clin Pract, 22, pp.37~44 (1993)
33. Yang JD, "Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease", Hepatology, 71, pp.907~916 (2020)
34. Kanwal F, "Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease", Gastroenterology, 155, pp.1828~1837 (2018)
35. Singh MK, "Diabetes and hepatocellular carcinoma : a pathophysiological link and pharmacological management", Biomed Pharmacother, 106, pp.991~1002 (2018)
36. Moon WS, "Overexpression of VEGF and angiopoietin 2 : a key to high vascularity of hepatocellular carcinoma?", Mod Pathol, 16, pp.552~557 (2003)
37. Popova EA, "Non-enzymatic glycosylation and deglycating enzymes", Biotechnol Biotechnol Equip, 24, pp.1928~1935 (2014)
38. Assi M, "The differential role of reactive oxygen species in early and late stages of cancer", Am J Physiol Regul Integr Comp Physiol, 313, pp.R646~R653 (2017)
39. Peverill W, "Evolving concepts in the pathogenesis of NASH : beyond steatosis and inflammation", Int J Mol Sci, 15, pp.8591~8638 (2014)
40. Wang TN, "Relationships between changes in leptin and insulin resistance levels in obese individuals following weight loss", Kaohsiung J Med Sci, 29, pp.436~443 (2013)
41. Coppack SW, "Adipose tissue changes in obesity", Biochem Soc Trans, 33(Pt 5), pp.1049~1052 (2005)
42. Cerf ME, "Beta cell dysfunction and insulin resistance", Front Endocrinol(Lausanne), 4, pp.37~ (2013)
43. Allaire M, "Type 2 diabetes-associated hepatocellular carcinoma: a molecular profile", Clin Liver Dis(Hoboken), 8, pp.53~58 (2016)
44. Yadav A, "Correlation of adiponectin and leptin with insulin resistance : a pilot study in healthy north Indian population", Indian J Clin Biochem, 26, pp.193~196 (2011)
45. Finucane FM, "Correlation of the leptin : adiponectin ratio with measures of insulin resistance in non-diabetic individuals", Diabetologia, 52, pp.2345~2349 (2009)
46. Tovar V, "IGF activation in a molecular subclass of hepatocellular carcinoma and preclinical efficacy of IGF-1R blockage", J Hepatol, 52, pp.550~559 (2010)
47. Chettouh H, "Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma", Liver Int, 35, pp.2203~2217 (2015)
48. Michelotti GA, "NAFLD, NASH and liver cancer", Nat Rev Gastroenterol Hepatol, 10, pp.656~665 (2013)
49. Fujii M, "A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma", Med Mol Morphol, 46, pp.141~152 (2013)
50. Flemming JA, "Risk prediction of hepatocellular carcinoma in patients with cirrhosis : the ADRESS-HCC risk model", Cancer, 120, pp.3485~3493 (2014)
51. Sharma SA, "Toronto HCC risk index : a validated scoring system to predict 10-year risk of HCC in patients with cirrhosis", J Hepatol, 68, pp.P92~P99 (2018)
52. Lambrecht J, "The APAC score : a novel and highly performant serological tool for early diagnosis of hepatocellular carcinoma in patients with liver cirrhosis", J Clin Med, 10, pp.3392~ (2021)
53. Fujiwara N, "Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease", Sci Transl Med, 14, pp.eabo4474~ (2022)
54. Weston SR, "Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease", Hepatology, 41, pp.372~379 (2005)
55. Ford ES, "Prevalence of the metabolic syndrome among US adults : findings from the third National Health and Nutrition Examination Survey", JAMA, 287, pp.356~359 (2002)
56. Bianco C, "Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores", J Hepatol, 74, pp.775~782 (2021)
57. Gellert-Kristensen H, "Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population", Hepatology, 72, pp.845~856 (2020)
58. Pelusi S, "Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease", Sci Rep, 9, pp.3682~ (2019)
59. Donati B, "MBOAT7 rs641738variant and hepatocellular carcinoma in non-cirrhotic individuals", Sci Rep, 7, pp.4492~ (2017)
60. Yang JD, "GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score", Cancer Epidemiol Biomarkers Prev, 28, pp.531~538 (2019)
61. Younes R, "Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease", J Hepatol, 75, pp.786~794 (2021)
62. Wu X, "Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma", Int J Biol Sci, 16, pp.1551~1562 (2020)
63. Ahn JC, "Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma", Hepatology, 73, pp.422~436 (2021)
64. Lee YT, "The role of extracellular vesicles in disease progression and detection of hepatocellular carcinoma", Cancers(Basel), 13, pp.3076~ (2021)
65. Kalinich M, "An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma", Proc Natl Acad Sci U S A, 114, pp.1123~1128 (2017)
66. Sun N, "Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring", Nat Commun, 11, pp.4489~ (2020)
67. Polesel J, "The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma", Ann Oncol, 20, pp.353~357 (2009)
68. Regimbeau JM, "Obesity and diabetes as a risk factor for hepatocellular carcinoma", Liver Transpl, 10(2 Suppl 1), pp.S69~S73 (2004)
69. Caldwell SH, "Obesity and hepatocellular carcinoma", Gastroenterology, 127(5Suppl 1), pp.S97~S103 (2004)
70. Abdel-Rahman O, "Cigarette smoking as a risk factor for the development of and mortality from hepatocellular carcinoma : an updated systematic review of 81 epidemiological studies", J Evid Based Med, 10, pp.245~254 (2017)
71. Amable G, "Metformin inhibits β-catenin phosphorylation on Ser-552 through an AMPK", PI3K, Int J Biochem Cell Biol, pp.2019, 112[DOI]
72. Loubière C, "Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells", Oncotarget, 6, pp.15652~15661 (2015)
73. Zhao B, "Anticancer mechanisms of metformin : a review of the current evidence", Life Sci, 254, pp.117717~ (2020)
74. Golay A, "Metformin and body weight", Int J Obes(Lond), 32, pp.61~72 (2008)
75. Chen HP, "Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner : population-based and in vitro studies", Gut, 62, pp.606~615 (2013)
76. Singh S, "Antidiabetic medications and the risk of hepatocellular cancer : a systematic review and meta-analysis", Am J Gastroenterol, 108, pp.881~891 (2013)
77. Kramer JR, "Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease", Hepatology, 75, pp.1420~1428 (2022)
78. Cunha V, "Metformin in the prevention of hepatocellular carcinoma in diabetic patients : a systematic review", Ann Hepatol, 19, pp.232~237 (2020)
79. Tseng CH, "Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes", Liver Int, 38, pp.2018~2027 (2018)
80. McGuire DK, "Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes : a meta-analysis", JAMA Cardiol, 6, pp.148~158 (2021)
81. Zelniker TA, "SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes : a systematic review and meta-analysis of cardiovascular outcome trials", Lancet, 393, pp.31~39 (2019)
82. Arvanitakis K, "The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma : from molecular mechanisms to potential clinical implications", Pharmacol Res, 181, pp.106261~ (2022)
83. Luo J, "Canagliflozin modulates hypoxia-induced metastasis, angiogenesis and glycolysis by decreasing HIF-1α protein synthesis via AKT", mTOR pathway, 2021, pp.22, 13336~
84. Benedetti R, "Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients : a meta-analysis of randomized clinical trials", Pharmacol Res, 175, pp.106039~ (2022)
85. El-Serag HB, "Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes", Gastroenterology, 136, pp.1601~1608 (2009)
86. Singh S, "Statins are associated with a reduced risk of hepatocellular cancer : a systematic review and meta-analysis", Gastroenterology, 144, pp.323~332 (2013)
87. Zou B, "Statin use and reduced hepatocellular carcinoma risk in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol (2022)[DOI]
88. Chen H, "Hepatic cyclooxygenase-2overexpression induced spontaneous hepatocellular carcinoma formation in mice", Oncogene, 36, pp.4415~4426 (2017)
89. Kern MA, "Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells", Hepatology, 36(4 Pt 1), pp.885~894 (2002)
90. Simon TG, "Association between aspirin use and risk of hepatocellular carcinoma", JAMA Oncol, 4, pp.1683~1690 (2018)

관련 논문AI추천